Global and China Monoclonal Antibody Industry Report, 2013

Publisher Name :
Date:1-Jan-2013
No. of pages: 100

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (Abbvie) and Trastuzumab (Roche) reached above USD5 billion around the globe, approximating 60% of global monoclonal antibody market.

Due to the features as high technical threshold, large capital demand and high rate of return, the international pharmaceutical giants (including Roche, Johnson & Johnson, Abbvie, Amgen, Novartis, etc.) are still accelerating the research and industrialization of monoclonal antibody agents through M&A or cooperation on the basis of existing monoclonal antibody products. For example, in April 2012, Amgen and AstraZeneca announced that they would jointly develop and sell the 5 monoclonal antibody agents of Amgen under research, namely, AMG827, AMG139, AMG181, AMG557 and AMG157.

Although the monoclonal antibody has witnessed rapid development, and the market scale is expected to share 8%-10% of world’s total in 2012, the market in China is still mainly occupied by imported products. As of the end of 2012, the number of imported monoclonal antibody products approved by SFDA amounted to 11, while that of domestic-made products only reached 8; the number of imported monoclonal antibody agents approved for clinical tests in China amounted to 27, while the figure of domestic products only hit 20, mainly imitating the overseas original drugs.

At present, the imported products as Rituximab, Trastuzumab, Cetuximab, Infliximab and Bevacizumab have contributed 70%-75% of monoclonal antibody market in China; the rest market is shared by the home-made drugs as Yisaipu®(Recombinant Human TNF Receptor-Ig Fusion Protein)and Xenopax® (Recombinant Humanized Anti-CD25 Monoclonal Antibody)of CPGJ, and Nimotuzomab of Biotech Pharma. Besides, several imported monoclonal antibody agents have accessed some local medical insurance systems. For example, Remicade®(Infliximab), which is used to treat rheumatoid, has accessed 11 local medical insurances, Simulect® (Bevacizumab, used in anti-transplant rejection) has accessed 10 local medical insurances, and Rituxan® (Rituximab, used to treat tumors) has accessed 9 local medical insurances. Meanwhile, since it may take 3-5 years for the domestic-made monoclonal antibody agents to achieve large scale and industrialized marketing, the imported markets will still embrace expectable development in future.

In view of the optimistic market prospect, advancement of monoclonal antibody technologies, support of favorable policies and the upcoming patent expiration of several key monoclonal antibody agents, multiple local enterprises as Hisun Pharmaceutical, Fosun Pharmaceutical, Walvax Biotechnology and SL Pharmaceutical are now marching into the monoclonal antibody market by huge capitals successively.

As of December 2012, the first monoclonal antibody generic drug (generic drug of enbrel) – Anbainuo® of Hisun Pharmaceutical was under phase III clinical supplementary test, and is expected to be approved by the end of 2013. The commercialized capacity will be 3.2 million pieces per year; furthermore, Enbrel has been tested in Brazil, etc., and is expected to achieve export.

In July 2012, the environmental impact assessment concerning phase I of new medicine pilot test base project (monoclonal antibody agents) of Fosun Pharmaceutical was publicized. According to the notice, the pilot scale of the project will be 130kg/a (equal to 1.3 million pcs/a of Rituximab), and the construction content involves raw material storage, pilot workshop, quality inspection, administration building and supporting public auxiliary facilities.

In April 2012, Walvax Biotechnology announced to jointly sign Cooperation Framework Agreement with Shanghai Fengmao Biotechnology, Shanghai Winlord Industries & Trading, and natural persons Wang Xiaofei and Kong Haiyan, planning to invest in Shanghai Fengmao in future four years, and research and industrialize Rituximab, Bevacizumab, Adalimumab, Panitumumab, Denosumab and long-acting EPO; in August, the company invested RMB246 million to establish the fully-owned subsidiary Shanghai Walvax, so as to promote the industrialization of the above six blockbuster bio-similar products. Nevertheless, according to the public information, the monoclonal antibody generic drugs of Walvax Biotechnology cannot be marketed until 2017 (Rituximab and Panitumumab as planned), and the commodity volume is expected to be 12kg/a, sharing 10% of planned capacity.

Global and China Monoclonal Antibody Industry Report, 2013 of ResearchInChina mainly involves the following contents:

  • Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry around the globe;
  • Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry in China;
  • Operation, monoclonal antibody business, development in China, R&D status, etc. of 6 monoclonal antibody enterprises around the globe and 10 enterprises in China.

Global and China Monoclonal Antibody Industry Report, 2013

Table Of Contents

1. Overview of Monoclonal Antibody Industry
1.1 Definition
1.2 Classification
1.3 Technological Development

2. Development of Global Monoclonal Antibody Industry
2.1 Development Situation
2.2 Market Scale
2.3 Competitive Pattern
2.4 Development Prospect and Forecast
2.4.1 Market Scale Forecast
2.4.2 Competitive Pattern Forecast
2.4.3 R&D Tendency Prediction

3. Monoclonal Antibody Industry in China
3.1 Development Situation
3.2 Market Scale
3.3 Market Segments
3.3.1 Rituximab/Rituxan®
3.3.2 Trastuzumab/Herceptin®
3.3.3 Cetuximab/Erbitux®
3.3.4 Nimotuzumab
3.3.5 Bevacizumab
3.3.6 Recombinant Human TNF Receptor-Ig Fusion Protein for Injection
3.4 Competitive Pattern
3.5 Development Prospect

4. Key Enterprises of Monoclonal Antibody Agents Overseas
4.1 Roche Pharmaceuticals
4.1.1 Profile
4.1.2 Operation
4.1.3 R&D and Investment
4.1.4 Monoclonal Antibody Business (Genentech)
4.1.5 Business in China
4.2 Johnson & Johnson
4.2.1 Profile
4.2.2 Operation
4.2.3 R&D and Investment
4.2.4 Monoclonal Antibody Business
4.2.5 Business in China
4.3 Merck
4.3.1 Profile
4.3.2 Operation
4.3.3 R&D and Investment
4.3.4 Monoclonal Antibody Business
4.3.5 Business in China
4.4 NOVARTIS
4.4.1 Profile
4.4.2 Operation
4.4.3 R&D and Investment
4.4.4 Monoclonal Antibody Business
4.4.5 Business in China
4.5 AbbVie (Abbott)
4.5.1 Profile
4.5.2 Operation
4.5.3 R&D and Investment
4.5.4 Monoclonal Antibody Business
4.5.5 Business in China
4.6 Amgen
4.6.1 Profile
4.6.2 Operation
4.6.3 R&D and Investment
4.6.4 Monoclonal Antibody Business
4.6.5 Business in China

5. Key Enterprises of Monoclonal Antibody Agents in China
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
5.1.1 Profile
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd.
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd.
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.1 Profile
5.2.2 Competitive Edges
5.2.3 Development Prospect
5.3 Chengdu Huasun Group Co., Ltd.
5.3.1 Profile
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.1 Profile
5.4.2 Monoclonal Antibody Business
5.5 Shanghai Yalian Antibody Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Monoclonal Antibody Business
5.6 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.6.1 Profile
5.6.2 Monoclonal Antibody Business
5.7 Yunnan Walvax Biotechnology Co., Ltd.
5.7.1 Profile
5.7.2 Monoclonal Antibody Business
5.8 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.8.1 Profile
5.8.2 Monoclonal Antibody Business
5.9 Beijing SL Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Monoclonal Antibody Business
5.10 Shenzhen Main Luck Pharmaceuticals Inc.
5.10.1 Profile
5.10.2 Monoclonal Antibody Business

List Of Charts

Composition of Monoclonal Antibody Agents Worldwide by Type, 2011
Technological Level of Monoclonal Antibody Agents in Developed Countries of Europe and America
Target Spots of Monoclonal Antibody Agents Approved by FDA by May 2012
R&D Fields of Therapeutic Antibody around the Globe, 2004 and 2011
Number of Monoclonal Antibody Agents (Including Clinical) Approved by FDA by May 2012
Sales of Monoclonal Antibody Agents Worldwide, 2009-2012
M&A Events Related to Monoclonal Antibody Worldwide (as of 2011)
Time to Market and Annual Sales of Major Monoclonal Antibody Agents around the Globe, 2010-2011
R&D Investment of Major Biopharmaceutical Companies Worldwide, 2009-2011
Expiration Date of Major Monoclonal Antibody Patents Worldwide
Competitive Analysis of Enbrel on American and Canadian Market
Several Cooperative Projects of Monoclonal Antibody Enterprises around the Globe, 2011-2012
Monoclonal Antibody Industrial Bases in China
Monoclonal Antibody Agents Approved in China as of December 2012
Technological Level Comparison of Monoclonal Antibody Agents at Home and Abroad
Sales of Monoclonal Antibody Agents in China, 2010-2012
Purchase Amount of Major Monoclonal Antibody Agents in Typical Hospitals of 22 Cities in China, 2009-2011
Purchase Amount of Rituximab in Sample Hospitals of China and YoY Growth, 2008-2011
Purchase Amount of Rituximab in Typical Hospitals of Three Major Cities in China, 2009-2011
Purchase Amount of Trastuzumab in Sample Hospitals of China, 2010-2011
Purchase Amount of Trastuzumab in Typical Hospitals of Three Major Cities in China, 2009-2011
Purchase Amount of Cetuximab in Sample Hospitals of China, 2010-2011
Sales Condition of Cetuximab/Erbitux in China, 2009-2011
Purchase Amount of Infilixmab in Hospitals of Three Major Cities in China, 2010-2011
Purchase Amount of Etanercept in Sample Hospitals of China and YoY Growth, 2009-2011
Purchase Amount of Etanercept in Hospitals of Three Major Cities in China, 2010-2011
Price Comparison of Yisaipu, Qiangke and Enbrel (Recombinant Human TNF Receptor-Ig Fusion Protein for Injection)
Death Causes Composition of Rural Residents in China, 2010
Monoclonal Antibody Products Accessing Local Medical Insurance in China
Several Monoclonal Antibody Products under Research in China (as of the end of 2011)
Listed Companies Investing in Monoclonal Antibody Industry in China, 2009-2012
Major M&A Cases of Roche, 1990-2010
Revenue and Operating Income of Roche, 2008-2012
Revenue of Roche by Business, 2010-2012
Revenue of Roche’s Pharmaceutical Business by Application, 2010-2011
Revenue of Roche by Region, 2010-2011
Revenue of Roche’s Pharmaceutical Business by Region, 2010-2012
R&D Investment of Roche by Business and % in Revenue, 2011
Sales of Roche’s (Genentech) Major Monoclonal Antibody Products Worldwide, 2010-2011
Sales of Roche’s Monoclonal Antibody Products by Region, 2010-2011
Investment of Roche in China
Sales Condition of Roche’s Rituximab in China, 2009-2011
Sales Condition of Roche’s Trastuzumab in China, 2009-2011
Revenue and Net Income of Johnson & Johnson, 2008-2011
Revenue Structure of Johnson & Johnson by Product, 2011
R&D Investment of Johnson & Johnson and % in Revenue, 2009-2011
Monoclonal Antibody Products of Johnson & Johnson
Sales of Johnson & Johnson’s Infliximab Worldwide, 2009-2011
Enterprises in China and Major Products of Johnson & Johnson
Import Value of Infliximab in China, 2010-2011
Revenue and Net Income of Merck, 2008-2011
Revenue of Merck by Product, Q3 2011 and Q3 2012
R&D Investment of Merck and % in Revenue, 2009-2011
Sales Condition of Cetuximab/Erbitux in China, 2009-2011
Revenue and Net Income of NVS, 2008-2012
Revenue Structure of NVS by Business, 2011
R&D Investment of NVS and % in Revenue, 2009-2011
NVS’s Monoclonal Antibody Products and Sales, 2011
Development History of NVS’s Pharmaceutical Business in China
Revenue of AbbVie by Product or Region, 2009-2011
R&D Investment of AbbVie, 2009-2011
Monoclonal Antibody Products and Sales of AbbVie, 2011
Global Sales of Adalimumab, 2007-2011
Revenue and Net Income of Amgen, 2008-2012
Revenue of Amgen by Product, 2009-2011
Revenue of Amgen by Region, 2009-2011
R&D Investment of Amgen and % in Revenue, 2008-2011
Product Lines of Amgen by the end of 2011
Marketized Monoclonal Antibody Products of Amgen (As of February 2012)
Revenue of Amgen’s Monoclonal Antibody Products for Sale, 2009-2011
Status Quo of Amgen’s Several Monoclonal Antibody Products under Research (As of February 2012)
Revenue of Amgen’s Enbrel by Region, 2009-2011
Patent Term of Enbrel
Revenue of Panitumumab by Region, 2009-2011
Patent Term of Panitumumab
Revenue of Amgen’s Denosumab by Region, 2010-2011
Revenue and Net Income of CP Guojian, 2008-2010
Several Monoclonal Antibody Products of CP Guojian under Research (As of June 2012)
Several Monoclonal Antibody Products of Zhangjiang Biotech under Research
Several Monoclonal Antibody Products of Biotech Pharmaceutical under Research
Revenue and Total Profit of Huasun Group, 2007-2010
Revenue of Huasun Biotech, 2007-2011
Revenue and Profit of Hisun Pharmaceutical, 2008-2012
Revenue and Profit of Walvax Biotechnology, 2007-2012
Monoclonal Antibody Technical Indicators of Shanghai Fengmao
R&D Progress of Shanghai Fengmao’s Five Monoclonal Antibody Generic Drugs (As of August 2012)
Revenue and Total Profit of Fosun Pharmaceutical, 2008-2012
Revenue and Operating Income of SL Pharmaceutical, 2007-2012

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global and China Monoclonal Antibody Industry Report, 2013-2017
    Published: 23-Dec-2013        Price: US $2500 Onwards        Pages: 118
    Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal......
  • Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
    Published: 15-Dec-2013        Price: US $3500 Onwards        Pages: 106
    GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease.Currently the primary treatment option......
  • Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth
    Published: 15-Dec-2013        Price: US $3500 Onwards        Pages: 89
    GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a num......
  • Patrys Limited – Product Pipeline Review – 2013
    Published: 30-Sep-2013        Price: US $1500 Onwards        Pages: 49
    Global Market Direct's pharmaceuticals report, "Patrys Limited Product Pipeline Review 2013" provides data on the Patrys Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.This report is built using data and information sourced from Global Markets Direct's proprietary databases, Patrys Limited's corporate website, SEC filings, investor presentations and fe......
  • Research Report on Global and China Monoclonal Antibody Industry, 2013-2017
    Published: 2-Aug-2013        Price: US $2200 Onwards        Pages: 50
    Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most i......
  • Monoclonal Antibody Markets in China
    Published: 1-May-2013        Price: US $4000 Onwards        Pages: 187
    China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.......
  • Synagis (Pediatric RSV) – Forecast and Market Analysis to 2022
    Published: 30-Apr-2013        Price: US $3495 Onwards        Pages: 48
    GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contac......
  • 2013 Deep Research Report on China Human Immunoglobulin Industry
    Published: 18-Mar-2013        Price: US $1800 Onwards        Pages: 116
    This is a professional and depth research report on China Human Immunoglobulin industry. This report has firstly introduced Human Immunoglobulin definition classification industry chain etc related information. Then introduced Human Immunoglobulin manufacturing technology and product specifications, And then summary statistics China major Human Immunoglobulin manufacturers 2010-2016 Human Immunoglobulin capacity production supply demand shortage and Human Immunoglobulin selling price cost gross ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs